“We are pleased to announce this strategic partnership with the government of Bangladesh, which demonstrates the company’s continued ability to leverage its proprietary C1 protein production platform to enhance, and in certain cases facilitate, the development and biomanufacturing infrastructure globally,” said Mark Emalfarb, Dyadic's President, and Chief Executive Officer. “Our primary focus remains speeding the adoption of our microbial platforms for use in developing and manufacturing biopharmaceutical vaccines and drugs faster, in larger quantities more affordably in developed and developing countries. This MoU is in line with Dyadic’s mission to help build the infrastructure in developing countries to increase access and affordability of biomanufacturing vaccines and drugs for infectious and other diseases that are being underserved.”

“Prime Minister of Bangladesh Sheikh Hasina time and again reiterates her sincere commitment for research and innovation. This MoU with the Government of Bangladesh will meet the demands of the people in Bangladesh. Working with American, European and other scientists in collaboration with Dyadic our youth can form long term research collaborations to discover new therapies for intractable diseases. My government will provide unflinching support to leverage such endeavor to benefit all nations in equal measures. Continuing to improve the health and well-being of our citizens is a key goal, vital for our ongoing success and there is increasing recognition that with systematic development of equal partnerships with developed nations and global companies, we can achieve this as well as actively contribute to the health of other nations. Initiatives such as these demonstrate and emphasise to the world how Bangladesh is transforming into a viable and increasingly valued, global partner.”

“Our collaboration with Dyadic is intended to facilitate cGMP biomanufacturing capacity development in terms of human resources and infrastructure in the field of biopharmaceutical research, pre-clinical vaccine and drug development and cGMP production, clinical trials, regulatory and other relevant areas of interest,” said Zahed Malek Bangladesh’s Minister of Health. “This collaboration has been spear headed in line with the honorable Prime Minister’s vision 2041 for creating a knowledge-based economy for a prosperous self-reliant Bangladesh to benefit our citizens as well as the global population.”

“Starting in 2021, we began working with Dyadic to develop a strategic plan that will be sustainable and affordable to address Bangladesh’s national bio security interests and to promote research, training, and dissemination of knowledge on health technology including but not limited to COVID-19 protein subunit vaccine development for the prevention and control of infectious and other diseases and improvement of public health programs within our country,” said Prof. (Dr) Ehsanul Kabir, Managing Director & CEO of Essential Drugs Company Limited. “I am very excited to go on this journey with Dyadic and their global scientific collaborators to increase access to affordable vaccines and drugs for everyone on the planet.”